<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:mp ids='MP_0005039'>Hypoxia</z:mp> inducible factors (HIFs) activate oncogenic pathways, while <z:chebi fb="0" ids="15033">thioredoxins</z:chebi> (Trx), including Trx1 and Trx reductases-1 and -2 (TrxR1 and TrxR2), promote HIF-alpha stabilization </plain></SENT>
<SENT sid="1" pm="."><plain>In immunoblotting studies in <z:hpo ids='HP_0002665'>lymphoma</z:hpo> cell lines we found that Raji and SUDHL4 cells exhibited normoxic HIF-2alpha protein stabilization </plain></SENT>
<SENT sid="2" pm="."><plain>Five cell lines showed increased TrxR1 expression, while only Namalwa, HF1 and SUDHL4 had Trx1 and TrxR2 activation </plain></SENT>
<SENT sid="3" pm="."><plain>Tissue microarrays in diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e>) and follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (FL) identified different HIF expression among histological subgroups (e.g. 44% <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> vs. 11% of FL cases with moderate-to-high expression of HIF-1alpha and HIF-2alpha, P = 0.0017) </plain></SENT>
<SENT sid="4" pm="."><plain>These data demonstrate that HIF and the <z:chebi fb="0" ids="15033">thioredoxin</z:chebi> family are abnormally activated in <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
</text></document>